Patients with depression show differences in gut microbial composition
This Chinese study aimed to characterize the gut microbiota of patients with major depressive disorder (MDD): one group of patients with acute MDD (who scored high on a depression scale, indicating clinically significant depression), called 'active-MDD', and a second group of patients with a history of MDD who had responded to treatment (achieving a 50% reduction in depression scale scores after 4 weeks of treatment), called 'responded-MDD'.
This Chinese study aimed to characterize the gut microbiota of patients with major depressive disorder (MDD): one group of patients with acute MDD (who scored high on a depression scale, indicating clinically significant depression), called ‘active-MDD’, and a second group of patients with a history of MDD who had responded to treatment (achieving a 50% reduction in depression scale scores after 4 weeks of treatment), called ‘responded-MDD’. Researchers compared fecal samples of these patients with those of healthy controls.
Despite great individual variability, there were some trends. Both MDD groups showed increased Bacteroidetes, Proteobacteria, and Actinobacteria, along with decreased Firmicutes, compared to the control group.
Researchers observed increased bacterial diversity in the fecal samples of active-MDD subjects, but not responded-MDD subjects, compared to controls. They also found a negative correlation between Faecalibacterium and the severity of depressive symptoms.
This study provides a ‘snapshot’ of the microbiota in depressed patients and does not address causality in humans. Further studies will elucidate whether the gut microbiota can be a biomarker for depression.
Jiang H, et al. (2015) Altered fecal microbiota composition in patients with major depressive disorder. Brain, Behavior, and Immunity doi:10.1016/j.bbi.2015.03.016
Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany.
His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions.
He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.
Following the GMFH 2022 Year at a Glance report, it is time for a flashback in the latest research on cancer microbiome. This post ranges between the epidemiology, etiology and diagnosis of cancer, looking at the role of fungal and bacterial gut microbiome in all three health care branches.
Significant strides have been made in our comprehension of the role of the gut microbiome in health and disease throughout the year 2022. We invite you to take a closer look at the "2022 Year at a Glance" report and learn about the groundbreaking discoveries made.
The Human Microbiome Action project is inviting experts in microbiome-based biomarker development to participate in a Delphi survey.